Tags

Type your tag names separated by a space and hit enter

A review of the current status of enteric vaccines.
P N G Med J. 1995 Dec; 38(4):325-31.PN

Abstract

Much progress has been made in developing vaccines against the most important enteric infections. Two new vaccines against typhoid fever (oral Ty21a and parenteral Vi polysaccharide) have been licensed in many countries. Newer, more sophisticated typhoid vaccines undergoing clinical testing include recombinant attenuated Salmonella typhi strains and Vi polysaccharide-carrier-protein conjugate vaccines. Two inactivated oral cholera vaccines, consisting of inactivated Vibrio cholerae O1 bacteria alone or in combination with B subunit of cholera toxin, each conferred 50-53% protection over three years in a field trial in Bangladesh where subjects were immunized with a three-dose regimen. An engineered live oral cholera vaccine, strain CVD 103-HgR, has been shown in extensive clinical trials to be well tolerated by children and adults in less developed countries and highly immunogenic following administration of just a single oral dose; a large-scale field trial of the efficacy of this vaccine is underway. In experimental challenge studies in volunteers, a single dose of CVD 103-HgR confers significant protection against challenge with wild-type V. cholerae O1 of either classical or El Tor biotype and either Inaba or Ogawa serotype. Several candidate vaccines against Shigella and enterotoxigenic Escherichia coli are in clinical trials. A multivalent rotavirus vaccine (rhesus reassortant vaccine) is undergoing extensive field testing in developed and less developed countries.

Links

patent databases

Authors+Show Affiliations

Levine MM
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.
Noriega F
No affiliation info available

MeSH

Adjuvants, ImmunologicAdministration, OralAdultBacterial Typing TechniquesBacterial VaccinesCarrier ProteinsChildCholeraCholera ToxinCholera VaccinesClinical Trials as TopicDeveloping CountriesDysentery, BacillaryEnterobacteriaceaeEnterobacteriaceae InfectionsEscherichia coliEscherichia coli InfectionsHumansPolysaccharides, BacterialRotavirusRotavirus InfectionsSalmonella typhiShigellaTyphoid FeverTyphoid-Paratyphoid VaccinesVaccines, AttenuatedVaccines, ConjugateVaccines, InactivatedVaccines, SyntheticVibrio choleraeViral Vaccines

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9522876

Citation

Levine, M M., and F Noriega. "A Review of the Current Status of Enteric Vaccines." Papua and New Guinea Medical Journal, vol. 38, no. 4, 1995, pp. 325-31.
Levine MM, Noriega F. A review of the current status of enteric vaccines. P N G Med J. 1995;38(4):325-31.
Levine, M. M., & Noriega, F. (1995). A review of the current status of enteric vaccines. Papua and New Guinea Medical Journal, 38(4), 325-31.
Levine MM, Noriega F. A Review of the Current Status of Enteric Vaccines. P N G Med J. 1995;38(4):325-31. PubMed PMID: 9522876.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A review of the current status of enteric vaccines. AU - Levine,M M, AU - Noriega,F, PY - 1995/12/1/pubmed PY - 1998/4/2/medline PY - 1995/12/1/entrez KW - Bacterial And Fungal Diseases KW - Biology KW - Cholera KW - Cholera--prevention and control KW - Delivery Of Health Care KW - Developing Countries KW - Diarrhea KW - Diarrhea--prevention and control KW - Diseases KW - Economic Factors KW - Gastrointestinal Effects KW - Health KW - Health Services KW - Immunization KW - Infections KW - Physiology KW - Primary Health Care KW - Research And Development KW - Technology KW - Vaccination KW - Vaccines KW - Viral Diseases SP - 325 EP - 31 JF - Papua and New Guinea medical journal JO - P N G Med J VL - 38 IS - 4 N2 - Much progress has been made in developing vaccines against the most important enteric infections. Two new vaccines against typhoid fever (oral Ty21a and parenteral Vi polysaccharide) have been licensed in many countries. Newer, more sophisticated typhoid vaccines undergoing clinical testing include recombinant attenuated Salmonella typhi strains and Vi polysaccharide-carrier-protein conjugate vaccines. Two inactivated oral cholera vaccines, consisting of inactivated Vibrio cholerae O1 bacteria alone or in combination with B subunit of cholera toxin, each conferred 50-53% protection over three years in a field trial in Bangladesh where subjects were immunized with a three-dose regimen. An engineered live oral cholera vaccine, strain CVD 103-HgR, has been shown in extensive clinical trials to be well tolerated by children and adults in less developed countries and highly immunogenic following administration of just a single oral dose; a large-scale field trial of the efficacy of this vaccine is underway. In experimental challenge studies in volunteers, a single dose of CVD 103-HgR confers significant protection against challenge with wild-type V. cholerae O1 of either classical or El Tor biotype and either Inaba or Ogawa serotype. Several candidate vaccines against Shigella and enterotoxigenic Escherichia coli are in clinical trials. A multivalent rotavirus vaccine (rhesus reassortant vaccine) is undergoing extensive field testing in developed and less developed countries. SN - 0031-1480 UR - https://www.unboundmedicine.com/medline/citation/9522876/A_review_of_the_current_status_of_enteric_vaccines_ L2 - https://www.lens.org/lens/search/patent/list?q=citation_id:9522876 DB - PRIME DP - Unbound Medicine ER -